131 related articles for article (PubMed ID: 32110224)
1. Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line.
Akhoundova Sanoyan D; Reiner CS; Papageorgiou P; Siebenhüner AR
Case Rep Oncol; 2020; 13(1):79-84. PubMed ID: 32110224
[TBL] [Abstract][Full Text] [Related]
2. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
3. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
4. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
5. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer.
Kieler M; Unseld M; Bianconi D; Prager GW
Memo; 2017; 10(3):136-140. PubMed ID: 28989542
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
Woo W; Carey ET; Choi M
Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
[TBL] [Abstract][Full Text] [Related]
7. Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Möhring C; Frontado Graffe FJ; Bartels A; Sadeghlar F; Zhou T; Mahn R; Marinova M; Feldmann G; Brossart P; Glowka TR; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
J Gastrointest Oncol; 2023 Feb; 14(1):352-365. PubMed ID: 36915455
[TBL] [Abstract][Full Text] [Related]
8. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.
Kipps E; Young K; Starling N
Ther Adv Med Oncol; 2017 Mar; 9(3):159-170. PubMed ID: 28344661
[TBL] [Abstract][Full Text] [Related]
9. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Cinar P; Ko AH
Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
[TBL] [Abstract][Full Text] [Related]
10. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
Chun JW; Woo SM; Lee SH; Choi JH; Park N; Kim JS; Cho IR; Paik WH; Lee WJ; Ryu JK; Kim YT
Ther Adv Med Oncol; 2022; 14():17588359221119539. PubMed ID: 36062047
[TBL] [Abstract][Full Text] [Related]
11. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Frampton JE
Drugs; 2020 Jul; 80(10):1007-1018. PubMed ID: 32557396
[TBL] [Abstract][Full Text] [Related]
12. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
Tang CY; Yang SH; Li CP; Su YY; Chiu SC; Bai LY; Shan YS; Chen LT; Chuang SC; Chan DC; Yen CJ; Peng CM; Chiu TJ; Chen YY; Chen JS; Chiang NJ; Chou WC
Pancreatology; 2024 Jun; 24(4):600-607. PubMed ID: 38565467
[TBL] [Abstract][Full Text] [Related]
13. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
[TBL] [Abstract][Full Text] [Related]
15. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
[TBL] [Abstract][Full Text] [Related]
16. Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.
Furuse J
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31382681
[TBL] [Abstract][Full Text] [Related]
17. A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer.
Kikuchi K; Umemura A; Nitta H; Katagiri H; Nishiya M; Uesugi N; Sugai T; Imanari K; Sasaki A
Surg Case Rep; 2022 Oct; 8(1):192. PubMed ID: 36205833
[TBL] [Abstract][Full Text] [Related]
18. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
20. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.
Chen LT; Macarulla T; Blanc JF; Mirakhur B; Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
